In a nutshell The aim of this trial is to determine the effect of the hormone therapy apalutamide (ARN-509) with or without abiraterone acetate (Zytiga), GnRH agonists or prednisone and whether they improve prostate surgery outcomes in men with high-risk prostate cancer. The outcomes to be measured include erectile function, continence, and effect on...
Read More
In a nutshell The aim of this study is to determine the effectiveness and safety of ipatasertib (GDC-0068) in combination with abiraterone (Zytiga) and prednisone/prednisolone (Deltasone) in men with metastatic castration-resistant prostate cancer. The main outcome to be measured is time to disease progression. The details Metastatic prostate...
Read More
In a nutshell This phase 2 trial aims to test the effectiveness of the combined treatment of three different immunotherapies. The main outcomes of this trial will be the tumor response to the treatment and the overall survival. The details Immunotherapies stimulate the immune system to attack and kill cancer cells the way it would a virus or...
Read More
In a nutshell This study examined accelerated partial breast irradiation (APBI) in comparison to whole breast irradiation (WBI) after surgery. They concluded that survival and long-term side-effects are the same for both treatments. However, ABPI had a higher rate of local recurrence as compared to WBI. Some background For early stage breast...
Read More
In a nutshell This study examined whether practicing Tibetan yoga during chemotherapy can benefit sleep quality. This study concluded that practicing twice a week or more led to greater long-term benefits over time. Some background Sleep disturbances and fatigue are common side effects reported by patients undergoing chemotherapy. This can...
Read More
In a nutshell This study examined whether radiotherapy treatment before surgery could improve disease-free survival, especially for patients with estrogen-receptor positive (ER+) breast cancer (dependent on the hormone estrogen for growth). This study concluded that radiotherapy before surgery improved disease-free survival. Some background For...
Read More
In a nutshell This study aimed to compare the outcomes for patients who received whole and partial breast radiotherapy after undergoing breast conservation surgery. This study concluded that partial breast radiotherapy and lower dose radiotherapy had similar outcomes for patients when compared to whole breast radiotherapy. Some background...
Read More
Video information: As part of our coverage from the 2017 American Society of Clinical Oncology annual meeting, Dr. Ryan Sullivan from Massachusetts General Hospital Cancer Center and Harvard Medical School provides a positive update for melanoma patients. Dr. Sullivan shares positive news related to PD-1 inhibitors and other promising advancements...
Read More
Video information: In this replay, medical oncologist/melanoma specialist Dr. Michael Postow joins Patient Power host Andrew Schorr online from Memorial Sloan Kettering Cancer Center to discuss combination therapies for patients with advanced melanoma. In the online chat, Andrew and Dr. Postow discuss how patients can get life-extending treatments...
Read More
In a nutshell This study examined the safety and effectiveness of durvalumab (Imfinzi) in patients with stage III non-small cell lung cancer. This study concluded that durvalumab delayed time to disease progression. Some background Chemotherapy and radiation are the standard treatment options for stage III non-small cell lung cancer (NSCLC, cancer...
Read More
In a nutshell This study assessed whether smoking increased the chance for spread of colorectal cancer (CRC) to the lungs. The study found that smoking may be a risk factor for cancer spread to the lungs. Some background Smoking is a known risk factor for colorectal cancer. Colorectal cancer is commonly known to spread to the liver when...
Read More
In a nutshell This meta-analysis summarizes studies that looked at the effectiveness of erlotinib in combination with chemotherapy. This review is specific for patients with advanced NSCLC. The authors concluded that this combination is effective for NSCLC patients who have never smoked and who have EGFR mutations. Some background Lung cancer is...
Read More
